Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Methemoglobinemia

  • Author: Mary Denshaw-Burke, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
 
Updated: Jan 04, 2016
 

Practice Essentials

Methemoglobinemia (congenital or acquired) occurs when red blood cells (RBCs) contain methemoglobin at levels higher than 1%. Methemoglobin results from the presence of iron in the ferric form instead of the usual ferrous form. This results in a decreased availability of oxygen to the tissues. Symptoms are proportional to the methemoglobin level and include skin color changes and blood color changes at levels up to 15% (see the image below). As levels rise above 15%, neurologic and cardiac symptoms arise as a consequence of hypoxia. Levels higher than 70% are usually fatal.

Note chocolate brown color of methemoglobinemia. I Note chocolate brown color of methemoglobinemia. In tubes 1 and 2, methemoglobin fraction is 70%; in tube 3, 20%; and in tube 4, normal.

See Clues on the Skin: Acute Poisonings, a Critical Images slideshow, to help diagnose patients based on their dermatologic presentations.

Key elements of the history include the following:

  • In congenital methemoglobinemia, characteristic diffuse persistent slate-gray cyanosis, often present from birth; patients are often asymptomatic despite the presence of cyanosis
  • In acute methemoglobinemia, which is usually acquired, a history of exposure to methemoglobinemia-inducing substances (not always available)
  • Any known family history of methemoglobinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency

Symptoms are proportional to the fraction of methemoglobin. A normal methemoglobin fraction is about 1% (range, 0-3%). Symptoms associated with higher levels of methemoglobin are as follows:

  • 3-15% - Slight discoloration (eg, pale, gray, blue) of the skin
  • 15-20% - Cyanosis, though patients may be relatively asymptomatic
  • 25-50% - Headache, dyspnea, lightheadedness (even syncope), weakness, confusion, palpitations, chest pain
  • 50-70% - Abnormal cardiac rhythms; altered mental status, delirium, seizures, coma; profound acidosis
  • >70% - Usually, death

Physical findings may include the following:

  • Discoloration of the skin and blood (the most striking physical finding)
  • Cyanosis – This occurs in the presence of 1.5 g/dL of methemoglobin (as compared with 5 g/dL of deoxygenated hemoglobin)
  • Seizures
  • Coma
  • Dysrhythmia (eg, bradyarrhythmia or ventricular dysrhythmia)
  • Acidosis
  • Cardiac or neurologic ischemia
  • Pallor of the skin or conjunctiva (suggestive of anemia and possible hemolysis)
  • Skeletal abnormalities and mental retardation

See Clinical Presentation for more detail.

Diagnosis

Laboratory studies that may be ordered include the following:

  • Studies to rule out hemolysis – Complete blood count (CBC), reticulocyte counts, lactate dehydrogenase (LDH), indirect bilirubin, haptoglobin
  • Studies to test for organ failure and general end-organ dysfunction – Liver function tests, electrolyte concentrations, blood urea nitrogen (BUN), creatinine
  • Urine pregnancy tests
  • Heinz body preparation
  • Hemoglobin electrophoresis to identify hemoglobin M (Hb M); some difficult cases require DNA sequencing of the globin chain gene or mass spectrometry for diagnosis
  • Specific enzyme assays for causative deficiencies
  • Bedside tests for methemoglobinemia - Examination of blood color on white filter paper after exposure to room air or after aerating a tube of blood with 100% oxygen; if the blood remains dark with these maneuvers, then methemoglobinemia is likely
  • Serum levels of nitrites or other offending drugs

Oxygen-carrying capacity of the blood may be determined with the help of the following:

  • Arterial blood gas (ABG) determination
  • Co-oximetry (if available)
  • Pulse oximetry (typically less accurate than co-oximetry in the setting of methemoglobinemia, with the exception of newer multiwavelength pulse oximeters)

Other studies that may be considered are as follows:

  • Potassium cyanide test to distinguish methemoglobin from sulfhemoglobin
  • CT of the head
  • Chest radiography to exclude pulmonary or cardiac disease
  • Echocardiography to determine the presence of congenital heart disease

See Workup for more detail.

Management

Early clinical recognition of methemoglobinemia is paramount. Treatment is determined by the symptoms:

  • Severe methemoglobinemia can be life-threatening and necessitate emergency therapy
  • Chronic mild methemoglobinemia may be completely asymptomatic and necessitate no specific therapy
  • No pharmacologic treatment exists for hereditary forms of methemoglobinemia

Initial care includes the following:

  • Administration of supplemental oxygen
  • Determination of the underlying etiology (eg, toxin or drug)
  • Removal of the offending oxidizing substance

After acute exposure to an oxidizing agent, it is advisable to treat patients with methemoglobin levels of 20% or higher (or lower levels, such as 10%, if there are significant comorbidities especially in the presence of end-organ dysfunction.

Treatment modalities include the following:

  • Methylene blue – This is the primary emergency treatment for documented symptomatic methemoglobinemia (contraindicated in G6PD deficiency and ineffective with hemoglobin M)
  • Exchange transfusion - This can be considered for patients who do not respond to methylene blue or G6PD-deficient individuals who are severely symptomatic
  • Hyperbaric oxygen treatment – This is another option when methylene blue therapy is ineffective or contraindicated
  • IV hydration and bicarbonate (for metabolic acidosis)
  • Other medications – These include ascorbic acid, riboflavin, cimetidine, and N -acetylcysteine
  • Dietary measures – Avoidance of precipitants in food or drink

See Treatment and Medication for more detail.

Next

Background

Methemoglobin contains iron in the ferric state (Fe3+) rather than the reduced ferrous form (Fe2+) found in hemoglobin. This structural change causes an alteration in the blood’s ability to bind oxygen. Methemoglobin is a naturally occurring oxidized metabolite of hemoglobin, and physiologic levels (< 1%) are normal. Problems arise as methemoglobin levels increase. Methemoglobin does not bind oxygen, thus effectively leading to a functional anemia.[1, 2, 3, 4]

In addition, methemoglobin causes a leftward shift of the oxygen-hemoglobin dissociation curve, resulting in decreased release of oxygen to the tissues. The presence of anemia and cyanosis despite oxygen treatment results from both of these effects.[4, 5] (See Pathophysiology and Etiology.)

Methemoglobinemia occurs when red blood cells (RBCs) contain methemoglobin at levels higher than 1%. This may be from congenital causes, increased synthesis, or decreased clearance. Increased levels may also result from exposure to toxins that acutely affect redox reactions, increasing methemoglobin levels.

Clinically, methemoglobinemia has a variable course (see Presentation). Because of the nonspecificity of the clinical findings, mild cases may go undiagnosed. Fatigue, flulike symptoms, and headaches may be the only manifestations in the initial phase. Symptoms are proportional to the methemoglobin level and include skin color changes (cyanosis with blue or grayish pigmentation) and blood color changes (brown or chocolate color). As levels of methemoglobin rise above 15%, neurologic and cardiac symptoms arise as a consequence of hypoxia. Levels higher than 70% are usually fatal.[4]

Tests to rule out hemolysis and to test for organ failure and general end-organ dysfunction should be performed. Urine pregnancy tests should be performed in females of childbearing age. Tests to evaluate a hereditary cause for methemoglobinemia should be ordered when appropriate. (See Workup.)

The most important aspects of the management of methemoglobinemia are recognition of the condition and prompt initiation of treatment, when indicated. For mild asymptomatic cases, treatment is purely for cosmetic or psychological reasons. When methemoglobinemia is severe or symptomatic, specific therapy may be indicated. Initial care includes supplemental oxygen and removal of the offending oxidizing substance. Various agents can reduce the methemoglobin levels to within the reference range or at least to acceptable levels. (See Treatment.)

Previous
Next

Pathophysiology

RBCs contain hemoglobin, which has a quaternary structure. Each hemoglobin molecule is composed of 4 polypeptide chains. Each of these chains is associated with a heme group, which contains iron in the reduced or ferrous form (Fe2+). In this form, iron can combine with oxygen by sharing an electron, thus forming oxyhemoglobin. When oxyhemoglobin releases oxygen to the tissues, the iron molecule is restored to its original ferrous state.

Hemoglobin can accept and transport oxygen only when the iron atom is in its ferrous form. When hemoglobin loses an electron and becomes oxidized, the iron atom is converted to the ferric state (Fe3+), resulting in the formation of methemoglobin. Methemoglobin lacks the electron that is needed to form a bond with oxygen and thus is incapable of oxygen transport.

Under normal conditions, methemoglobin levels remain below 1%; however, under conditions that cause oxidative stress, levels will rise. The low level of methemoglobin is maintained through 2 important mechanisms. The first is the hexose-monophosphate shunt pathway within the erythrocyte. Through this pathway, oxidizing agents are reduced by glutathione.

The second and more important mechanism involves two enzyme systems, diaphorase I and diaphorase II, and requires nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH), respectively, to reduce methemoglobin to its original ferrous state.

NADH-dependent methemoglobin reduction (diaphorase I pathway) is the major enzymatic system involved.[6] Cytochrome b5 reductase plays a major role in this process by transferring electrons from NADH to methemoglobin, an action that results in the reduction of methemoglobin to hemoglobin. This enzyme system is responsible for the removal of 95-99% of the methemoglobin that is produced under normal circumstances.

NADPH-dependent methemoglobin reduction (diaphorase II pathway) usually plays only a minor role in the removal of methemoglobin. This enzyme system utilizes glutathione production and glucose-6-phosphate dehydrogenase (G6PD) to reduce methemoglobin to hemoglobin. It assumes a larger and more important role in methemoglobin regulation in patients with cytochrome b5 reductase deficiencies.

The NADPH-dependent methemoglobin reduction pathway can be accelerated by exogenous cofactors such as methylene blue to as much as five times its normal level of activity.[3, 7, 6, 8] In the absence of further accumulation of methemoglobin, these methemoglobin reduction pathways can clear methemoglobin at a rate of approximately 15% per hour.

Acquired methemoglobinemia is considerably more common than congenital forms.

Congenital (hereditary) methemoglobinemia

At least two forms of congenital cytochrome b5 reductase deficiency exist. Both are inherited in an autosomal recessive pattern. In type Ib5R deficiency, the more common form, cytochrome b5 reductase is absent only in RBCs. Homozygotes appear cyanotic but usually are otherwise asymptomatic. Methemoglobin levels typically range from 10% to 35%. Life expectancy is not adversely influenced, and pregnancies are not complicated. Heterozygotes may develop acute, symptomatic methemoglobinemia after exposure to certain drugs or toxins.

The type IIb5R form is substantially less common, accounting for only 10-15% of cases of congenital cytochrome b5 reductase deficiency. In this condition, cytochrome b5 reductase is deficient in all cells, not just RBCs. It is associated with several other medical problems, including mental retardation, microcephaly, and other neurologic complications. Life expectancy is severely compromised, and patients usually die at a very young age. The exact mechanism of the neurologic complications is not known.

Methemoglobinemia may also involve the presence of abnormal hemoglobins (hemoglobin M [Hb M]). In most of these hemoglobins, tyrosine replaces the histidine residue, which binds heme to globin. This replacement displaces the heme moiety and permits oxidation of the iron to the ferric state. Consequently, Hb M is more resistant to reduction by the methemoglobin reduction enzymes (see above). This results in a functionally impaired hemoglobin with a decreased affinity for oxygen.

The inheritance pattern for Hb M variants is autosomal dominant, whereas that for methemoglobinemia due to cytochrome b5 reductase deficiency is autosomal recessive. Patients with Hb M appear cyanotic but are otherwise generally asymptomatic. There are three phenotypic varieties of Hb M, corresponding to the globulin gene affected (alpha, beta, or gamma) as follows[6, 9, 10] :

  • Alpha-chain variants cause neonatal cyanosis that is persistent
  • Beta-chain variants do not cause cyanosis until several months after birth, when the level of fetal hemoglobin has decreased
  • Gamma-chain variants cause transient neonatal cyanosis that resolves once the level of fetal hemoglobin decreases

Another hemoglobin variant, hemoglobin E (Hb E), is associated with methemoglobinemia as well. In a study from the National Thalassemia Center in Sri Lanka, 45 patients who had a diagnosis of Hb E beta-thalassemia were found to have significantly higher median methemoglobin levels that normal control subjects and patients with other hemoglobinopathies (2.7% vs 0.3%.) Furthermore, methemoglobin levels were significantly elevated in patients who had undergone a previous splenectomy.[11]

Acquired methemoglobinemia

Acquired methemoglobinemia is much more common than the congenital form and involves excessive production of methemoglobin. The incidence may be much higher than is documented. Often, this is associated with the use of or exposure to oxidant drugs, chemicals, or toxins, including dapsone,[12] local anesthetic agents,[13] and nitroglycerin. This increased production overwhelms the normal physiologic regulatory and excretory mechanisms. These oxidant agents can cause an increase in methemoglobin levels either by ingestion or by absorption through the skin. A study involving two tertiary care teaching hospitals, indicated that methemoglobinemia was present in a significant proportion of all hospitalized patients, and the frequency may be much more than anticipated or expected.[14]

The presence of methemoglobin may also be a marker and predictor of sepsis, resulting from release of excessive amounts of nitrous oxide (NO).[15]

Clinical manifestations

Organs with high oxygen demands (eg, the central nervous system [CNS] and the cardiovascular system) usually are the first systems to manifest toxicity. Oxygenated blood is bright red, deoxygenated blood is dark red, and blood containing methemoglobin is dark reddish brown (see the image below). This dark hue is responsible for clinical cyanosis.

Note chocolate brown color of methemoglobinemia. I Note chocolate brown color of methemoglobinemia. In tubes 1 and 2, methemoglobin fraction is 70%; in tube 3, 20%; and in tube 4, normal.

Clinical evidence of cyanosis depends on the level of methemoglobin. Skin discoloration can occur in patients who are not anemic when as little as 1.5 g/dL (about 10%) of hemoglobin is in the form of methemoglobin. By comparison, a deoxyhemoglobin level of 5 g/dL is required to produce clinical cyanosis. When methemoglobin levels are relatively low, cyanosis may be observed without cardiopulmonary symptoms.

In methemoglobinemia, cyanosis is usually the first presenting symptom. In other conditions associated with cyanosis resulting from hypoxemia, it is a much later finding.

In patients with severe anemia, a higher percentage of methemoglobin is required for cyanosis to be obvious. These patients are more likely to exhibit signs of hypoxemia and have less cyanosis than is seen in patients who do not have anemia.

Previous
Next

Etiology

Congenital (hereditary) methemoglobinemia

Hereditary methemoglobinemias may be divided into two categories as follows[16] :

  • Methemoglobinemia due to an altered form of hemoglobin (ie, Hb M)
  • Methemoglobinemia due to an enzyme deficiency (NADH reductase deficiency) that decreases the rate of reduction of iron in the hemoglobin molecule

Several variants of hemoglobin M have been described, including Hb Ms, Hb MIwate, Hb MBoston, Hb MHyde Park, and Hb MSaskatoon. These are usually autosomal dominant in nature. Alpha-chain substitutions cause cyanosis at birth, whereas the effects of beta-chain substitutions become clinically apparent in infants at 4-6 months of age.

There are four types of hereditary methemoglobinemias that are secondary to deficiency of NADH cytochrome b5 reductase, which is encoded by the CYB5R3 gene. All of them are autosomal recessive disorders. Heterozygotes have 50% enzyme activity and no cyanosis; homozygotes that have elevated methemoglobin levels above 1.5% have clinical cyanosis. The four types are as follows:

  • Type I – This is the most common variant, and the enzyme deficiency is limited to the erythrocytes causing cyanosis; cyanosis usually, but not always, develops during infancy [17]
  • Type II – Widespread deficiency of the enzyme occurs in various tissues, including erythrocytes, liver, fibroblasts, and brain; it is associated with severe CNS symptoms, including encephalopathy, microcephaly, hypertonia, athetosis, opisthotonos, strabismus, mental retardation, and growth retardation; cyanosis is evident at an early age
  • Type III – Although the hematopoietic system (platelets, RBCs, and white blood cells [WBCs]) is involved, the only clinical consequence is cyanosis
  • Type IV – Like type I, this type has isolated involvement of the erythrocytes but results in chronic cyanosis

Deficiency of NADPH-flavin reductase can also cause methemoglobinemia.

Acquired methemoglobinemia

Acquired methemoglobinemia is usually due to the ingestion of drugs or toxic substances. Exposure to such substances in amounts that exceed the enzymatic reduction capacity of RBCs precipitates symptoms.[14] Acquired methemoglobinemia is more frequent in premature infants and infants younger than 4 months, and the following factors may have a role in the higher incidence in this age group:

  • Fetal hemoglobin may oxidize more easily than adult hemoglobin
  • The level of NADH reductase is low at birth and increases with age; it reaches adult levels by age 4 months
  • Higher gastric pH in infants may facilitate bacterial proliferation, resulting in increased conversion of dietary nitrates to nitrites
  • An association between methemoglobinemia and acute gastroenteritis in infants has been noted in several studies. This may be due to acidosis from loss of stool bicarbonate, which impairs the already immature function of the methemoglobin reductase system in these young patients

Organic and inorganic nitrites and nitrates are common causes of methemoglobinemia. Many of these substances can also be absorbed through the skin, and many prescription cardiac medications contain these compounds. Treatment of preterm infants with inhaled nitric oxide may lead to methemoglobinemia; susceptibility to methemoglobinemia in these infants may be increased by carriage of a single-nucleotide polymorphism in the CYB5R3 gene.[18]

Dietary intake may occur in infants or adults who ingest well water that has been contaminated with nitrites caused by water runoff from fertilized fields.[19] Prepackaged foods may contain significant levels of nitrites.[20, 21]

Chlorates are another group of oxidizing agents that can cause methemoglobinemia. These substances are found in matches, explosives, and fungicides.

Topical and injected local anesthetics (eg, benzocaine,[14, 22] lidocaine, prilocaine, phenazopyridine,[23, 24] cerium nitrate, and silver sulfadiazine[25] ) have also caused methemoglobinemia. Predisposing factors for the development of this toxicity include the presence of a mucosal injury with resultant increased absorption or a previously undiagnosed methemoglobin reductase enzyme deficiency. This toxicity can also be idiosyncratic.

In a 10-year retrospective case-control study of 33 methemoglobinemia cases in patients undergoing a total of 94,694 procedures in which topical anesthetics were used, including bronchoscopy, nasogastric tube placement, esophagogastroduodenoscopy, transesophageal echocardiography, and endoscopic retrograde cholangiopancreatography, Chowdhary and colleagues found a low overall prevalence of methemoglobinemia (035%). However, risk was increased in hospitalized patients and those who received benzocaine-based anesthetics.[26]

Dapsone, a drug used to prevent and treat Pneumocystis jiroveci pneumonia (PCP) and to treat leprosy and other skin diseases (including a topical preparation used for acne[27] ), has also been associated with methemoglobinemia. This drug should be used with great caution in patients with known G6PD deficiency, methemoglobin reductase deficiency, or Hb M.[14, 28]

Patients with low catalase activity (inherited or acquired) may be at risk for the development of methemoglobinemia secondary to the formation of hydrogen peroxide after being treated with rasburicase for tumor lysis syndrome.[29, 30, 31] Some authors have suggested that catalase activity be measured before rasburicase therapy is initiated in this setting.

RBCs in patients with liver cirrhosis undergo severe oxidative stress, especially in the setting of bleeding complications.[32] The level of methemoglobin is significantly higher in the RBCs of these patients than in those of nonbleeding patients.

Idiopathic methemoglobinemia can occur in association with systemic acidosis. This typically occurs in infants younger than 6 months and is usually caused by dehydration and diarrhea. Idiopathic methemoglobinemia is exacerbated by the lower levels of methemoglobin reductase enzyme found in infants (50% of adult levels).

Inadequately cooked vegetables (eg, spinach, beets, carrots) contaminated with bacteria have been associated with methemoglobinemia. Infants and patients on gastric acid−reduction therapy are particularly vulnerable to methemoglobinemia because gastric acid production may not be sufficient to maintain low levels of nitrate-reducing bacteria in the intestine.) Fava bean ingestion in patients with G6PD deficiency is another potential dietary cause of methemoglobinemia.[33]

Other substances that can cause methemoglobinemia include the following:

  • Copper sulfate
  • Organic compounds – Sodium chlorite, [34] ammonium carbonate (smelling salts), [35] and 2,4-dinitrophenol (weight loss agent) [36]
  • Recreational drugs – Phenylamine (psychoactive stimulant), [37] cocaine, [38] and volatile nitrates [39]
  • Antimalarials – Primaquine, chloroquine, [40] and sitamaquine [41]
  • Antineoplastic agents – Cyclophosphamide, ifosfamide, flutamide, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone [42]
  • Analgesics and antipyretics – Acetaminophen, acetanilide, phenacetin, and celecoxib
  • Zopiclone [43]
  • Herbicides and insecticides – Paraquat (dipyridylium), indoxacarb, [44] and aluminum phosphide [45]
  • Methylene blue (high dose or in G6PD-deficient patients [46] )
  • Indigo carmine
  • Resorcinol
  • Metoclopramide [47]
  • Antibiotics – Sulfonamides, nitrofurans, and para-aminosalicylic acid
  • Industrial/household agents – Aniline dyes, nitrobenzene, naphthalene (moth balls), aminophenol, and nitroethane (nail polish remover)
Previous
Next

Epidemiology

United States statistics

Hereditary methemoglobinemia is rare. The most common cause of congenital methemoglobinemia is cytochrome b5 reductase deficiency (type Ib5R). This enzymatic deficiency is endemic in certain Native American tribes (Navajo and Athabaskan Alaskans).

Most cases of methemoglobinemia are acquired and result from exposure to certain drugs or toxins. One of the more common causes of acquired methemoglobinemia is exposure to topical benzocaine during medical procedures. An estimated 0.115% of patients undergoing transesophageal echocardiography (TEE) develop methemoglobinemia.[13, 48, 49]

A large retrospective cohort study found a high incidence of methemoglobinemia (up to 19.8%) in 167 pediatric patients receiving dapsone for PCP prophylaxis.[50] The median methemoglobin level was 9% (range, 3.5-22.4%). The risk of developing methemoglobinemia was increased in those patients receiving a higher dose of dapsone (≥20% above the target dosage of 2 mg/kg/day).

A retrospective study from 2 large teaching hospitals in the United States identified 138 cases of acquired methemoglobinemia over a period of 28 months.[14]

International statistics

Methemoglobinemia occurs rarely throughout the world. Cytochrome b5 reductase deficiency (type Ib5R) is also endemic in the Yakutsk people of Siberia.

Age-related demographics

Children, especially those younger than 4 months, are particularly susceptible to methemoglobinemia. The primary erythrocyte protective mechanism against oxidative stress is the NADH system. In infants, this system has not fully matured, and the NADH methemoglobin reductase activity and concentrations are low. Children between the ages of 6 and 10 years may have higher baseline levels of methemoglobinemia than adults do.[51]

Free iron deposition in the brains of sudden fetal and infant death victims has been identified as a possible catabolic product of maternal methemoglobinemia and may be a marker of maternal nicotine exposure.[52]

Sex-related demographics

The inheritance pattern of the congenital enzyme deficiency form of the disease is autosomal recessive. Hb M is inherited in an autosomal dominant pattern. There is no association between sex and the frequency of congenital methemoglobinemia. However, because G6PD deficiency is X-linked, there is a higher risk of acquired methemoglobinemia in males with G6PD deficiency when they are subjected to oxidative stress. Otherwise, no difference exists between males and females with respect to the incidence of acquired methemoglobinemia.

Race-related demographics

The congenital form of methemoglobinemia due to cytochrome b5 reductase deficiency (type Ib5R) is endemic in certain ethnic groups. These groups include the Navajo, Athabaskan Alaskans, and the Yakutsk people in Siberia. Because G6PD deficiency is a risk factor for acquired methemoglobinemia, populations in which such deficiency is endemic, including populations of Mediterranean and African descent, are at higher risk for acquired methemoglobinemia.

Previous
Next

Prognosis

The prognosis of mild cases of methemoglobinemia is very favorable. In severe cases, the prognosis is determined by the degree of anoxic end-organ damage. Complications of methemoglobinemia may include myocardial infarction, seizure, coma, and death. As methemoglobin levels increase, patients demonstrate evidence of cellular hypoxia. Death occurs when methemoglobin fractions approach 70%. Complications, including death, can occur at lower levels in patients with significant comorbidities.

The clinical course of hereditary forms of methemoglobinemia is generally benign. Patients are usually asymptomatic, except for the presence of chronic cyanosis. However, individuals with type IIb5 cytochrome reductase deficiency have a markedly shortened life expectancy, primarily because of multiple neurologic complications.

Acquired methemoglobinemia is usually mild but may be severe and rarely fatal, depending on the cause. Mild-to-moderate transient methemoglobinemia may be present but may escape clinical detection; a high index of suspicion must be maintained.[53]

Patients with acquired methemoglobinemia due to toxin exposure can be severely ill when diagnosed. In some case, acquired toxic methemoglobinemia can be life-threatening, particularly when the exposure is intentional or the condition is not recognized. One fatality and 3 near-fatalities were reported in a study of 138 patients.[14] However, acquired toxic methemoglobinemia usually responds to treatment when it is recognized and properly treated.

Previous
Next

Patient Education

Patients with inherited methemoglobinemia should be counseled regarding the avoidance of toxins, chemicals, and certain drugs (eg, dapsone). Genetic counseling is important. Treatment of type II cases does not prevent or reverse CNS progression.

Patients with both congenital and acquired methemoglobinemia should receive instructions regarding avoidance of precipitating factors.

Patients who develop methemoglobinemia from the oxidant stress of pharmaceutical agents should be warned about other potent oxidant compounds. Patients who develop methemoglobinemia secondary to environmental exposure require a meticulous workup to prevent reexposure to the offending agent. All workplace or household members should be evaluated.

Patients receiving therapy for chronic methemoglobinemia should receive adequate information regarding the risks and benefits expected with treatment.

For patient education resources, see Anemia.

Previous
 
 
Contributor Information and Disclosures
Author

Mary Denshaw-Burke, MD, FACP Clinical Assistant Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Clinical Assistant Professor, Affiliated Clinical Faculty of the Lankenau Institute for Medical Research; Program Director of Hematology/Oncology Fellowship, Education Coordinator for Oncology, Lankenau Medical Center

Mary Denshaw-Burke, MD, FACP is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Coauthor(s)

Mudra Kumar, MD, MRCP, FAAP Professor of Pediatrics, Course Director, Course 6 MSII, Preclerkship Director, Clinical Integration, Department of Pediatrics, University of South Florida Morsani College of Medicine

Mudra Kumar, MD, MRCP, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Deric C Savior, MD Fellow, Department of Hematology/Oncology, Lankenau Hospital

Disclosure: Nothing to disclose.

Amy Lawser Curran, MD Fellow, Department of Hematology/Oncology, Lankenau Hospital

Amy Lawser Curran, MD is a member of the following medical societies: Alpha Omega Alpha, Sigma Xi

Disclosure: Nothing to disclose.

Elizabeth DelGiacco, DO Chief Fellow, Department of Hematology/Oncology, Main Line Health, Lankenau Medical Center

Elizabeth DelGiacco, DO is a member of the following medical societies: American Society of Hematology, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Acknowledgements

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, and International Society for Experimental Hematology

Disclosure: Nothing to disclose.

Matthew Bouchard, MD Consulting Staff, Department of Emergency Medicine, Altoona Regional Health System

Disclosure: Nothing to disclose.

Michael J Burns, MD Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center

Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, and Southwest Oncology Group

Disclosure: Nothing to disclose.

Max J Coppes, MD, PhD, MBA Senior Vice President, Center for Cancer and Blood Disorders, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University School of Medicine; Clinical Professor of Pediatrics, George Washington University School of Medicine and Health Sciences

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Kathy L Ferguson, DO Attending Physician, Department of Emergency Medicine, New York Hospital of Queens

Kathy L Ferguson, DO is a member of the following medical societies: American College of Emergency Physicians and American College of Medical Toxicology

Disclosure: Nothing to disclose.

Lance W Kreplick, MD, FAAEM, MMM Medical Director of Hyperbaric Medicine, Fawcett Wound Management and Hyperbaric Medicine; Consulting Staff in Occupational Health and Rehabilitation, Company Care Occupational Health Services; President and Chief Executive Officer, QED Medical Solutions, LLC

Lance W Kreplick, MD, FAAEM, MMM, is a member of the following medical societies: American Academy of Emergency Medicine and American College of Physician Executives

Disclosure: Nothing to disclose.

David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School

David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Sharada A Sarnaik, MBBS Professor of Pediatrics, Wayne State University School of Medicine; Director, Sickle Cell Center, Attending Hematologist/Oncologist, Children's Hospital of Michigan

Sharada A Sarnaik, MBBS is a member of the following medical societies: American Association of Blood Banks, American Association of University Professors, American Society of Hematology, American Society of Pediatric Hematology/Oncology, New York Academy of Sciences, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians and American Society of Hematology

Disclosure: Nothing to disclose.

John Schoffstall, MD Associate Professor, Department of Emergency Medicine, Medical College of Pennsylvania

John Schoffstall, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Pennsylvania Medical Society, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Michael J Verive, MD Medical Director, Pediatric Intensive Care, Department of Pediatrics, St Mary's Hospital for Women and Children

Michael J Verive, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, Pediatric Sedation, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Bloom J, ed. Comprehensive Toxicology. Amsterdam, Netherlands: Elsevier; 1997. Vol 4: 62-6.

  2. Curry S. Methemoglobinemia. In: Rosen P, Barkin R, Danzl DF, et al, eds. Emergency Medicine: Concepts and Clinical Practice. 4th ed. St Louis, Mo: Mosby-Year Book; 1997.

  3. Hoffman R, Benz E, Shattil S, Furie B, Cohen H, eds. Hematology Basic Principles and Practice. 4th ed. New York, NY: Churchill Livingstone; 2005. 650-7.

  4. do Nascimento TS, Pereira RO, de Mello HL, Costa J. Methemoglobinemia: from diagnosis to treatment. Rev Bras Anestesiol. 2008 Nov-Dec. 58(6):657-64, 651-7. [Medline]. [Full Text].

  5. Percy MJ, McFerran NV, Lappin TR. Disorders of oxidised haemoglobin. Blood Rev. 2005 Mar. 19(2):61-8. [Medline].

  6. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol. 1993 Jan. 42(1):7-12. [Medline].

  7. Curry S. Methemoglobinemia. Ann Emerg Med. 1982 Apr. 11(4):214-21. [Medline].

  8. Goluboff N, Wheaton R. Methylene blue induced cyanosis and acute hemolytic anemia complicating the treatment of methemoglobinemia. J Pediatr. 1961 Jan. 58:86-9. [Medline].

  9. Gebara BM, Goetting MG. Life-threatening methemoglobinemia in infants with diarrhea and acidosis. Clin Pediatr (Phila). 1994 Jun. 33(6):370-3. [Medline].

  10. Bento C, Magalhães Maia T, Carvalhais I, Moita F, Abreu G, Relvas L, et al. Transient neonatal cyanosis associated with a new Hb F variant: Hb F Viseu. J Pediatr Hematol Oncol. 2013 Mar. 35(2):e77-80. [Medline].

  11. Allen A, Fisher C, Premawardhena A, Bandara D, Perera A, Allen S. Methemoglobinemia and ascorbate deficiency in hemoglobin E ß thalassemia: metabolic and clinical implications. Blood. 2012 Oct 11. 120(15):2939-44. [Medline].

  12. Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. Ann Pharmacother. 1998 May. 32(5):549-53. [Medline].

  13. Grauer SE, Giraud GD. Toxic methemoglobinemia after topical anesthesia for transesophageal echocardiography. J Am Soc Echocardiogr. 1996 Nov-Dec. 9(6):874-6. [Medline].

  14. Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004 Sep. 83(5):265-73. [Medline].

  15. Ohashi K, Yukioka H, Hayashi M, Asada A. Elevated methemoglobin in patients with sepsis. Acta Anaesthesiol Scand. 1998 Jul. 42(6):713-6. [Medline].

  16. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999 Nov. 34(5):646-56. [Medline].

  17. Forestier A, Pissard S, Cretet J, Mambie A, Pascal L, Cliquennois M, et al. Congenital Recessive Methemoglobinemia Revealed in Adulthood: Description of a New Mutation in Cytochrome b5 Reductase Gene. Hemoglobin. 2015 Jul 31. 1-4. [Medline].

  18. Fuller TD, Spracklen CN, Ryckman KK, Knake LA, Busch TD, Momany AM, et al. Genetic variation in CYB5R3 is associated with methemoglobin levels in preterm infants receiving nitric oxide therapy. Pediatr Res. 2015 Mar. 77 (3):472-6. [Medline].

  19. Fan AM, Steinberg VE. Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Regul Toxicol Pharmacol. 1996 Feb. 23(1 pt 1):35-43. [Medline].

  20. Erkekoglu P, Baydar T. Evaluation of nitrite contamination in baby foods and infant formulas marketed in Turkey. Int J Food Sci Nutr. 2009 May. 60(3):206-9. [Medline].

  21. [Guideline] Greer FR, Shannon M. Infant methemoglobinemia: the role of dietary nitrate in food and water. Pediatrics. 2005 Sep. 116(3):784-6. [Medline].

  22. Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med. 2004 Jun 14. 164(11):1192-6. [Medline].

  23. Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg. 2009 Mar. 108(3):837-45. [Medline].

  24. So TY, Farrington E. Topical Benzocaine-induced Methemoglobinemia in the Pediatric Population. J Pediatr Health Care. 2008 Nov-Dec. 22(6):335-9. [Medline].

  25. Kath MA, Shupp JW, Matt SE, Shaw JD, Johnson LS, Pavlovich AR. Incidence of methemoglobinemia in patients receiving cerium nitrate and silver sulfadiazine for the treatment of burn wounds: a burn center's experience. Wound Repair Regen. 2011 Mar-Apr. 19(2):201-4. [Medline].

  26. Chowdhary S, Bukoye B, Bhansali AM, Carbo AR, Adra M, Barnett S, et al. Risk of topical anesthetic-induced methemoglobinemia: a 10-year retrospective case-control study. JAMA Intern Med. 2013 May 13. 173(9):771-6. [Medline].

  27. Watton C, Smith K, Carter E. Methemoglobinemia as a complication of topical dapsone. N Engl J Med. 2015 Jan 29. 372 (5):492. [Medline]. [Full Text].

  28. Skold A, Klein R. Symptomatic-Low Grade Methemoglobinemia Because of Dapsone: A Multiple Hit Hypothesis. Am J Ther. 2011 Jun 3. [Medline].

  29. Henretig FM, Gribetz B, Kearney T, Lacouture P, Lovejoy FH. Interpretation of color change in blood with varying degree of methemoglobinemia. J Toxicol Clin Toxicol. 1988. 26(5-6):293-301. [Medline].

  30. Góth L, Bigler NW. Catalase deficiency may complicate urate oxidase (rasburicase) therapy. Free Radic Res. 2007 Sep. 41(9):953-5. [Medline].

  31. Bauters T, Mondelaers V, Robays H, De Wilde H, Benoit Y, De Moerloose B. Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. Int J Clin Pharm. 2011 Feb. 33(1):58-60. [Medline].

  32. Geetha A, Lakshmi Priya MD, Jeyachristy SA, Surendran R. Level of oxidative stress in the red blood cells of patients with liver cirrhosis. Indian J Med Res. 2007 Sep. 126(3):204-10. [Medline]. [Full Text].

  33. Odièvre MH, Danékova N, Mesples B, Chemouny M, Couque N, Parez N, et al. Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy. Int J Hematol. 2011 May. 93(5):664-6. [Medline].

  34. Romanovsky A, Djogovic D, Chin D. A case of sodium chlorite toxicity managed with concurrent renal replacement therapy and red cell exchange. J Med Toxicol. 2013 Mar. 9(1):67-70. [Medline].

  35. Warriner DR, Morris P, Ramjiani V, Morton A, Sheridan P. Smells like a heart attack, but is it?. BMJ Case Rep. 2011. 2011:[Medline].

  36. Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol. 2011 Sep. 7(3):205-12. [Medline].

  37. Severe methemoglobinemia and hemolytic anemia from aniline purchased as 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), a recreational drug, on the Internet - Oregon, 2011. MMWR Morb Mortal Wkly Rep. 2012 Feb 10. 61(5):85-8. [Medline].

  38. Weichert I. Acute management of cocaine-associated methaemoglobinaemia. Case Rep Med. 2011. 2011:136396. [Medline].

  39. Hunter L, Gordge L, Dargan PI, Wood DM. Methaemoglobinaemia associated with the use of cocaine and volatile nitrites as recreational drugs: a review. Br J Clin Pharmacol. 2011 Jul. 72(1):18-26. [Medline].

  40. Carmona-Fonseca J, Alvarez G, Maestre A. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg. 2009 Feb. 80(2):188-93. [Medline].

  41. Loiseau PM, Cojean S, Schrével J. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite. 2011 May. 18(2):115-9. [Medline].

  42. Kunos CA, Radivoyevitch T, Ingalls ST, Hoppel CL. Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. Future Oncol. 2012 Feb. 8(2):145-50. [Medline]. [Full Text].

  43. Fung HT, Lai CH, Wong OF, Lam KK, Kam CW. Two cases of methemoglobinemia following zopiclone ingestion. Clin Toxicol (Phila). 2008 Feb. 46(2):167-70. [Medline].

  44. Park JS, Kim H, Lee SW, Min JH. Successful treatment of methemoglobinemia and acute renal failure after indoxacarb poisoning. Clin Toxicol (Phila). 2011 Oct. 49(8):744-6. [Medline].

  45. Mostafazadeh B, Pajoumand A, Farzaneh E, Aghabiklooei A, Rasouli MR. Blood levels of methemoglobin in patients with aluminum phosphide poisoning and its correlation with patient's outcome. J Med Toxicol. 2011 Mar. 7(1):40-3. [Medline].

  46. Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med. 1971 Jul. 75(1):83-6. [Medline].

  47. Grossmann J, Neuwald S, Wiese B. [Acute respiratory failure after metoclopramide for methemoglobinemia - a rare and potentially life-threatening side effect]. Z Gastroenterol. 2012 Jun. 50(6):585-8. [Medline].

  48. Vallurupalli S, Das S, Manchanda S. Infection and the Risk of Topical Anesthetic Induced Clinically Significant Methemoglobinemia after Transesophageal Echocardiography. Echocardiography. 2009 Aug 31. [Medline].

  49. Jiminez MA, Polena S, Coplan NL, Patel K, Gintautas J. Methemoglobinemia and transesophageal echo. Proc West Pharmacol Soc. 2007. 50:134-5. [Medline].

  50. Esbenshade AJ, Ho RH, Shintani A, Zhao Z, Smith LA, Friedman DL. Dapsone-induced methemoglobinemia: a dose-related occurrence?. Cancer. 2011 Aug 1. 117(15):3485-92. [Medline].

  51. Rechetzki KF, Henneberg R, da Silva PH, do Nascimento AJ. Reference values for methemoglobin concentrations in children. Rev Bras Hematol Hemoter. 2012. 34(1):14-6. [Medline]. [Full Text].

  52. Lavezzi AM, Mohorovic L, Alfonsi G, Corna MF, Matturri L. Brain iron accumulation in unexplained fetal and infant death victims with smoker mothers--the possible involvement of maternal methemoglobinemia. BMC Pediatr. 2011 Jul 6. 11:62. [Medline]. [Full Text].

  53. Yano SS, Danish EH, Hsia YE. Transient methemoglobinemia with acidosis in infants. J Pediatr. 1982 Mar. 100(3):415-8. [Medline].

  54. Chaurasia S, Ramappa M, Bhargava A. Corneal epitheliopathy in congenital methemoglobinemia. Cornea. 2014 Apr. 33(4):422-4. [Medline].

  55. Yusim Y, Livingstone D, Sidi A. Blue dyes, blue people: the systemic effects of blue dyes when administered via different routes. J Clin Anesth. 2007 Jun. 19(4):315-21. [Medline].

  56. Zaki SA, Jadhav A, Chandane P. Methaemoglobinaemia during Holi festival. Ann Trop Paediatr. 2009 Sep. 29(3):221-3. [Medline].

  57. Kohli-Kumar M, Zwerdling T, Rucknagel DL. Hemoglobin F-Cincinnati, alpha 2G gamma 2 41(C7) Phe-->Ser in a newborn with cyanosis. Am J Hematol. 1995 May. 49(1):43-7. [Medline].

  58. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm. Accessed: December 23, 2015.

  59. Martinez A, Sanchez-Valverde F, Gil F, Clerigué N, Aznal E, Etayo V, et al. 78 Cases Of Methemoglobinemia Induced By Vegetable Intake In Infants In North Spain. A Case-Control Study. J Pediatr Gastroenterol Nutr. 2013 Jan 1. [Medline].

  60. Bergamaschi MM, Alcantara GK, Valério DA, Queiroz RH. Curcumin could prevent methemoglobinemia induced by dapsone in rats. Food Chem Toxicol. 2011 Jul. 49(7):1638-41. [Medline].

 
Previous
Next
 
Note chocolate brown color of methemoglobinemia. In tubes 1 and 2, methemoglobin fraction is 70%; in tube 3, 20%; and in tube 4, normal.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.